Imprinted Long Non-Coding RNAs in Mammalian Development and Disease.
Autorzy:
Di Michele F; Institute of Molecular Genetics of Montpellier (IGMM), CNRS, 1919 Route de Mende, 34093 Montpellier, France.; University of Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France. Chillón I; Institute of Molecular Genetics of Montpellier (IGMM), CNRS, 1919 Route de Mende, 34093 Montpellier, France.; University of Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France. FeilR; Institute of Molecular Genetics of Montpellier (IGMM), CNRS, 1919 Route de Mende, 34093 Montpellier, France.; University of Montpellier, 163 Rue Auguste Broussonnet, 34090 Montpellier, France.
Recent developments in cGMP research: From mechanisms to medicines and back.
Autorzy:
Lukowski R; Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany. FeilR; Interfakultäres Institut für Biochemie (IFIB), University of Tübingen, Tübingen, Germany.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2022 Jun; Vol. 179 (11), pp. 2321-2327. Date of Electronic Publication: 2022 Mar 25.
Visualising and understanding cGMP signals in the cardiovascular system.
Autorzy:
FeilR; Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen, Germany. Lehners M; Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen, Germany. Stehle D; Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen, Germany. Feil S; Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen, Germany.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2022 Jun; Vol. 179 (11), pp. 2394-2412. Date of Electronic Publication: 2021 May 22.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
Autorzy:
Stehle D; Interfakultäres Institut für Biochemie (IFIB), University of Tübingen, Tübingen, Germany. Xu MZ; Institute of Vegetative Physiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Schomber T; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany. Hahn MG; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany. Schweda F; Institut für Physiologie, Universität Regensburg, Regensburg, Germany. Feil S; Interfakultäres Institut für Biochemie (IFIB), University of Tübingen, Tübingen, Germany. Kraehling JR; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany. Eitner F; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany.; Division of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany. Patzak A; Institute of Vegetative Physiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Sandner P; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany.; Institute of Pharmacology, Hannover Medical School, Hannover, Germany. FeilR; Interfakultäres Institut für Biochemie (IFIB), University of Tübingen, Tübingen, Germany. Bénardeau A; Bayer AG, Cardiovascular Research, Pharma Research Center, Wuppertal, Germany.; Novo Nordisk A/S, Cardio-Renal Biology, Måløv, Denmark.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2022 Jun; Vol. 179 (11), pp. 2476-2489. Date of Electronic Publication: 2021 Jul 03.
Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
Autorzy:
Tchernychev B; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Li H; Departments of Medicine and Cell Biology, Albert Einstein College of Medicine, New York, New York, USA. Lee SK; Departments of Medicine and Cell Biology, Albert Einstein College of Medicine, New York, New York, USA. Gao X; Departments of Medicine and Cell Biology, Albert Einstein College of Medicine, New York, New York, USA. Ramanarasimhaiah R; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Liu G; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Hall KC; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Bernier SG; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Jones JE; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Feil S; Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany. FeilR; Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany. Buys ES; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Graul RM; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA. Frenette PS; Departments of Medicine and Cell Biology, Albert Einstein College of Medicine, New York, New York, USA. Masferrer JL; Cyclerion Therapeutics Inc., Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
British journal of pharmacology [Br J Pharmacol] 2021 Sep; Vol. 178 (17), pp. 3463-3475. Date of Electronic Publication: 2021 May 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
